ISGE Series
Series Editor: Andrea R. Genazzani

Andrea R. Genazzani Mark Brincat *Editors* 

# Frontiers in Gynecological Endocrinology

Volume 1 From Symptoms to Therapies





Andrea R. Genazzani • Mark Brincat Editors

## Frontiers in Gynecological Endocrinology

Volume 1: From Symptoms to Therapies







Editors
Andrea R. Genazzani
International Society of Gynecological
Endocrinology
Pisa
Italy

Mark Brincat
Department of Obstetrics and Gynaecology
Mater Dei Hospital
Birkirkara
Malta

ISSN 2197-8735 ISSN 2197-8743 (electronic)
ISBN 978-3-319-03493-5 ISBN 978-3-319-03494-2 (eBook)
DOI 10.1007/978-3-319-03494-2
Springer Cham Heidelberg New York Dordrecht London

Library of Congress Control Number: 2014930748

© Springer International Publishing Switzerland 2014

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

#### **ISGE Series**

Series Editor Andrea R. Genazzani

For further volumes: http://www.springer.com/series/11871

#### **List of Contributors**

**Ibrahim Alkatout** Department of Obstetrics and Gynecology, University Hospitals Schleswig-Holstein, Kiel, Germany

**Silvia DiBello** Division of Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

**Guja Bernacchi** Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Johannes Bitzer Department of Obstetrics and Gynecology, Women's Hospital, University Hospital Basel, Basel, Switzerland

Mark Brincat Department of Obstetrics and Gynaecology, Mater Dei Hospital, Birkirkara, Malta

**Anna Brona** Department of Endocrinology, Diabetology and Isotope Therapy, Wrocław Medical University, Wroclaw, Poland

**Jean Calleja-Agius** Department of Obstetrics and Gynaecology, Mater Dei Hospital, Birkirkara, Malta

**Adrian Campelo** Division of Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

**Elena Cecchi** Division of Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Elisa Chierchia Department of Obstetrics and Gynecology, Gynecological Endocrinology Center, University of Modena and Reggio Emilia, Modena, Italy

Maria Creatsas 2nd Department of Obstetrics and Gynecology, University of Athens-Aretaieio Hospital, Athens, Greece

**George K. Creatsas** 2nd Department of Obstetrics and Gynecology, University of Athens-Aretaieio Hospital, Athens, Greece

**Andrea R. Genazzani** Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

**Alessandro D. Genazzani** Department of Obstetrics and Gynecology, Gynecological Endocrinology Center, University of Modena and Reggio Emilia, Modena, Italy

**Marie O. Gerval** Department of Gynaecology, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK

Royal Brompton and Harefield NHS Foundation Trust, London, UK

**Magdalena Montt Guevara** Division of Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

**Haitham Hamoda** The Assisted Conception Unit, King's College Hospital, London, UK

**Diana Jędrzejuk** Department of Endocrinology, Diabetology and Isotope Therapy, Wrocław Medical University, Wrocław, Poland

**Abdusattarova Khulkar** Department of Obstetrics and Gynecology, University Hospitals Schleswig-Holstein, Kiel, Germany

**Felicja Lwow** Department of Health Promotion, Faculty of Physiotherapy, University School of Physical Education, Wroclaw, Poland

**Paolo Mannella** Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

**Liselotte Mettler** Department of Obstetrics and Gynecology, University Hospitals Schleswig-Holstein, Kiel, Germany

**Andrzej Milewicz** Department of Health Promotion, Faculty of Physiotherapy, University School of Physical Education, Wroclaw, Poland

**Monica Mittal** The Assisted Conception Unit, King's College Hospital, London, UK

**Rossella E. Nappi** Department of Obstetrics and Gynaecology, Research Centre for Reproductive Medicine, University of Pavia, Pavia, Italy

**Giulia Palla** Division of Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

**Nick Panay** Queen Charlotte's & Chelsea and Chelsea & Westminster Hospitals, Imperial College, London, UK

**Silvia Pisaneschi** Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

List of Contributors xi

Alessia Prati Department of Obstetrics and Gynecology, Gynecological Endocrinology Center, University of Modena and Reggio Emilia, Modena, Italy

**Erika Rattighieri** Department of Obstetrics and Gynecology, Gynecological Endocrinology Center, University of Modena and Reggio Emilia, Modena, Italy

**Federica Ricchieri** Department of Obstetrics and Gynecology, Gynecological Endocrinology Center, University of Modena and Reggio Emilia, Modena, Italy

**Susanna Santagni** Department of Obstetrics and Gynecology, Gynecological Endocrinology Center, University of Modena and Reggio Emilia, Modena, Italy

**Michael Savvas** The Assisted Conception Unit, King's College Hospital, London, UK

**Joseph G. Schenker** Department Obstetrics Gynecology, Hadassah Medical Centre, Hebrew University, Jerusalem, Israel

**Tommaso Simoncini** Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

**Stefania Spina** Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

**Thomas E. J. Stevenson** Department of Surgery, Frimley Park Hospital NHS Foundation Trust, Frimley, Surrey, UK

**John C. Stevenson** National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, London, UK

John Studd London PMS and Menopause Centre, London, UK

#### Contents

#### Part I Menstrual Dysfunction in Young Women

1	Amenorrhea	3
2	<b>Dysfunctional Uterine Bleeding During Adolescence</b> Maria Creatsas and George K. Creatsas	9
3	Dysmenorrhea, Premenstrual Syndrome, and Premenstrual Dysphoric Disorder	15
4	Noncontraceptive Benefits of 17β-Estradiol COCs  During Adolescence	25
5	The Concept of Endometriosis as Chronic Disease: Surgical and Medical Therapy with Hormonal and Nonhormonal Targets and the Influence of Endometriosis on Obstetrical Outcome Liselotte Mettler, Wael Sammur, and Ibrahim Alkatout	29
	t II Metabolism, Hyperandrogenism, Body Weight and roduction	
6	Vitamin D, Metabolic Disorders and Reproduction Diana Jędrzejuk, Andrzej Milewicz, Felicja Lwow, and Anna Brona	51
7	PCOS from Lifestyle to the Use of Inositol and Insulin Sensitizers  Alessandro D. Genazzani, Alessia Prati, Giulia Despini Giulia Marini, and Federica Ricchieri	59

8	Pathophysiology and Clinical Assessment of Hyperandrogenic States Susanna Santagni, Erika Rattighieri, Elisa Chierchia, Giulia Despini, and Alessandro D. Genazzani	69
Par	t III Ovarian Stimulation, Surgery and Insufficiency	
9	Ovarian Surgery from Puberty Through Reproductive Age and After Menopause	79
10	Ovulation Induction: Adverse Effects	103
11	Premature Ovarian Insufficiency and Its Fertility Implications Michael Savvas and Haitham Hamoda	119
12	Premature Ovarian Insufficiency: Strategies to Preserve Good Health and Fertility	127
13	Treatment with Donor Eggs	135
Par	t IV Quality of Life and Sexual Health	
14	Hypoactive Sexual Desire Disorder	143
15	<b>Quality of Life and Sexual Health in Breast Cancer Survivors</b> Johannes Bitzer	157
Par	t V Hormone and Pregnancy	
16	Thyroid Disorders and Pregnancy: Diagnostic and Therapeutic Proposal	171
17	The Role of Progesterone in the Prevention of Preterm Labour Jean Calleja-Agius and Mark Brincat	179
Par	t VI Ovarian Ageing and Menopause	
18	Therapeutic Management of the Menopausal Transition	191

19	Menopause-Related Changes in the Musculoskeletal System, Cartilages and Joints	201
20	<b>Is It Safe to Prevent and Treat Postmenopausal Osteoporosis?</b> John C. Stevenson and Thomas E.J. Stevenson	207
21	Menopause, Aging, Pelvic Organ Prolapse, and Dysfunction Silvia Pisaneschi, Giulia Palla, Stefania Spina, Guja Bernacchi, Elena Cecchi, Silvia Di Bello, Magdalena Montt Guevara, Adrian Campelo, and Tommaso Simoncini	215
22	The Influence of Sex Steroids on Affairs of the Heart John C. Stevenson and Marie O. Gerval	225
23	Reproductive Depression and the Response to Oestrogen Therapy	233
24	<b>Body Identical Hormone Replacement</b>	241
25	Postmenopause and Ageing: The Concept of Personalized Therapy	
Ind	ex	257

#### Part I

#### Menstrual Dysfunction in Young Women

此为试读,需要完整PDF请访问: www.ertongbook.com



### Pathophysiology and Clinical Assessment of Primary Amenorrhea

George K. Creatsas and Maria Creatsas

A significant number of adolescents present menstrual irregularities during the first 2 gynecological years. The absence of menses is defined as amenorrhea and is classified as primary or secondary. Primary amenorrhea (PA) is the absence of menstruation in 16-year-old girls with developed secondary characteristics or in 14-year-old girls with no presence of secondary characteristics. Secondary amenorrhea is defined as the absence of menstrual period, for 6 months or more, in women who had previously normal or irregular menses [1–4, 11].

The classification of PA, in relation to the etiology of the disease, includes the uterovaginal aplasia or congenital uterovaginal anomalies with obstruction, endocrine disorders, chromosomal anomalies, as well as stress and psychological problems [5–7].

Uterovaginal anomalies with obstruction needs immediate repair following excision or/and reconstruction of the obstructive area (vaginal diaphragm or imperforate hymen).

Endocrine disorders presented with PA include cases of congenital adrenal hyperplasia, hypothalamic or pituitary amenorrhea, the premature ovarian failure, and the polycystic ovarian syndrome (PCOS) [8, 9].

PA due to chromosomal anomalies includes cases of gonadal dysgenesis, hermaphroditism, etc. (Fig.1.1) [1, 2]. Gonadal dysgenesis (streak gonads) may be present either with normal XX and XY karyotypes or abnormal karyotypes. The Turner syndrome (45X0) is usually diagnosed in early childhood because of the well-known phenotypic characteristics (short stature, webbed neck, and low hairline), and therefore many patients do not present for assessment of PA.

Stress and psychological problems are common causes of PA in young girls including cases of athletic amenorrhea.

G.K. Creatsas (⋈) • M. Creatsas

<sup>2</sup>nd Department of Obstetrics and Gynecology, University of Athens-Aretaieio Hospital,

<sup>76</sup> Vas Sofias Ave., Athens 11528, Greece

e-mail: geocre@aretaieio.uoa.gr; geocre@aretaieio.uoa.gr




Fig. 1.1 Primary hypogonadism ([2], modified)

Another classification, including the relative incidence of PA causes, is presented in Table 1.1 [1–3, 5, 10–14].

Delayed puberty (DP) is the absence of onset of puberty by >2 SD, later than the average age of menarche. DP is also the absence of menstruation in 13–14-year-old girls who have no secondary sexual characteristic development. The causes of DP are (1) general: constitutional delay of growth and puberty, underweight, and other chronic diseases; (2) gonadal origin (hypergonadotropic hypogonadism): prodromal premature ovarian failure—karyotypically normal, Turner's syndrome, and pure gonadal dysgenesis; (3) autoimmune oophoritis; (4) 17,20-desmolase deficiency; (5) radiation or chemotherapy; (6) FSH receptor mutation; (7) galactosemia; (8) congenital hypogonadotropic hypogonadism; (9) gonadotropin deficiency; and (10) hypothalamic/pituitary lesions [3, 5, 11–14].


Patient's evaluation includes information taken by the clinical history, gynecological and physical examination, X-rays, ultrasonography (US), the hormonal profile of the patient, and rarely endoscopic evaluation (Fig. 1.2).

#### 1.1 Case Presentations

1. Two girls 16 and 18 years old, presented with PA and periodic pelvic pain. The second girl also reported difficulty in sexual intercourse. Both had normal secondary sexual characteristics. The gynecological examination and the ultrasonography revealed *vaginal aplasia and atresia of the hymen*, *respectively*. Both were surgically treated.

**Table 1.1** Classification and incidence of PA cases

- No breast development and low follicle-stimulating hormone (FSH) (30 % of PA cases)
  - Constitutional delay (10 %)
  - Prolactinomas (5 %)
  - Kallmann syndrome (2 %)
  - Other central nervous system lesions (3 %)
  - Stress, weight loss, and anorexia (3 %)
  - PCOS (3 %)
  - Congenital adrenal hyperplasia (3 %)
  - Other reasons (1 %)
- No breast development: high FSH (40 % of PA cases)
  - 46 XX (15 %)
  - 46 XY (5 %)
  - Abnormal (20 %)
- Breast development (30 % of PA)
  - Mullerian agenesis (10 %)
  - Androgen insensitivity (9 %)
  - Vaginal septum (2 %)
  - Imperforate hymen (1 %)
  - Constitutional delay (8 %)



- Turner's syndrome
- Androgen insensitivity

LH: (luteinizing hormone), US: (ultrasound)

**Fig. 1.2** Approach to adolescent PA [3, 4, 11, 13]

- 2. A young girl 16 years old presented with PA and short stature. The examination showed absence of secondary sexual characteristics. The karyotype revealed *XO*—gonadal dysgenesis. Management: hormone replacement therapy (HRT).
- 3. Adolescent 18.5 years old. Personal history: hypotonia, congenital cataract. Family history: Hashimoto's thyroiditis and endometrial polyp (mother). Height: 1.54 m (8th percentile), weight: 59 kg (58th percentile). Body mass

- index (BMI): 24.8 kg/m<sup>2</sup>. Breast: Tanner III, pubic hair: Tanner IV. US: small uterine volume. FSH: 46.6 mIU/mL, LH: 15.3 mIU/mL, 17 estradiol (E2): <9 pg/mL and anti-Mullerian hormone: 0.2 pmol/L. Karyotype: normal (46, XX). DEXA scan: osteoporosis. US evaluation: ovarian volume: 1.6 mL and 1.89 mL, respectively, endometrium not visible, uterus small. Diagnosis: primary ovarian insufficiency (POI) or failure (*The combination of POI, congenital cataract and hypotonia poses suspicion of Marinesco–Sjogren syndrome, a rare genetic disease*). Management: HRT, calcium plus vitamin D supplement. Recommendation: light weight lifting exercise.
- 4. Adolescent 16 years old. Free family history. Athlete. Exercise >2 h/day. Height: 1.56 m, weight: 39 kg, BMI: 16.02 kg/m². Gynecological and physical examination: Breast: Tanner V, pubic hair: Tanner V. Gynecological examination: normal. Laboratory tests: normal. PRL, testosterone, free testosterone, dehydroepiandrosterone sulfate (DHEA-S), 17-OH progesterone (17-OH-prog), sex hormone binding globulin (SHBG), thyroid-stimulating hormone (TSH): normal. FSH: 0.3 mIU/mL, LH: 0.7 mIU/mL, E2: 12.3 pg/mL. Luteinizing hormone releasing test (LH-RH test): positive. DEXA scan: osteopenia. US evaluation: ovarian volume: 3 mL and 4 mL, respectively, endometrium: 1 mm, uterus: small. *Diagnosis: functional hypothalamic amenorrhea*. Management: HRT. Consultation: to improve body weight.
- 5. Adolescent 14 years old. Height: 1.49 m (5th percentile), weight: 50 kg (50th percentile), BMI: 22.52 kg/m², breast: Tanner I, pubic hair: Tanner I. Gynecological examination: normal. PRL, DHEA-S, 17-OH-progesterone, SHBG, TSH: normal. FSH: 1 mIU/mL, LH: <0.5 mIU/mL, E2: 10 pg/mL, LH-RH test: poor response. Magnetic resonance imaging (MRI)—pituitary: normal. US evaluation: small uterine and ovarian volume. *Diagnosis: Idiopathic hypogonadotropic hypogonadism*, *GnRH deficiency*, *and GnRH insensitivity*. Anosmia not present. Management: HRT.
- 6. Adolescent 15 years old. Free family and personal history. Height: 1.76 m, weight: 60 kg, BMI: 19.3 kg/m². Breast: Tanner III, pubic hair: Tanner IV, gynecological exam: normal. FSH, LH, E2, Testo, DHEA-S, 17-OH-Prog, SHBG, TSH: normal. PRL (0', 30'): 50 ng/mL and 45 ng/mL. MRI: pituitary microadenoma. US evaluation: ovarian volume: 5.3 mL and 4.15 m, respectively, endometrium: 7 mm. *Diagnosis*: *hypophyseal microadenoma*. Management: bromocriptine 1.25 mg × 2.
- 7. Adolescent 16 years old. *Athlete*. Gynecological and physical examination: Normal. US evaluation: atrophic endometrium. FSH, LH: 10.5 mIU and 15.3 mIU/mL, respectively. E<sub>2</sub>: 5.3 pg/mL. Treatment COCs.
- 8. Adolescent 15 years old. Low BMI <18 kg/m², gynecological examination: normal, physical examination: No acne or hirsutism, breast: Tanner II, hormonal evaluation: FSH: 16.3 mIU/mL, LH: 18.6 mIU/mL, PRL: normal, E2: 5.6 pg/mL. *Diagnosis: anorexia nervosa*. Management: psychiatric consultation and COCs.

Each patient should be individually treated, avoiding unnecessary tests and overtreatment. In cases presented with obstruction of the genital route immediate surgery is advised. If hormonal treatment is scheduled, the low-dose, new-generation  $17\beta$ -estradiol COCs are recommended. Explanation, reassurance, and emotional support are necessary tools for the management of the disease, as in many cases treatment is advisable for a long period of time.

#### References

- ASRM Practice Committee (2008) Current evaluation of amenorrhea. Fertil Steril 90: S219–S225
- 2. American Society for Reproductive Medicine (ASRM) (2006) The practice committee of the ASRM. Fertil Steril 86(Suppl 4):S148–S155
- 3. Creatsas G, Deligeoroglou E, Christopoulos P (2010) Creation of a neovagina after Creatsas modification of Williams vaginoplasty for the treatment of 200 patients with Mayer Rokitansky Kyster Hauser syndrome. Fertil Steril 94(5):1848–1852
- Diaz A, Laufer MR, Breech LL (2006) Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics 118(5):2245–2250
- 5. Deligeoroglou E, Tsimaris P (2010) Menstrual disturbances in puberty. Best Pract Res Clin Obstet Gynaecol 24(2):157–171
- Hickey M, Balen A (2003) Menstrual disorders in adolescence: investigation and management.
   Hum Reprod Update 9(5):493–504
- 7. Patel SS, Bamigboye V (2007) Hyperprolactinaemia. J Obstet Gynaecol 9(5):493-504
- 8. Deligeoroglou E, Tsimaris P, Deliveliotou A, Christopoulos P, Creatsas G (2006) Menstrual disorders during adolescence. Pediatr Endocrinol Rev 3(Suppl 1):150–159
- Slap GB (2003) Menstrual disorders in adolescence. Best Pract Res Clin Obstet Gynaecol 17 (1):75–92
- Creatsas G (1996) Hormone replacement therapy in gonadal dysgenesis cases. Gynecol Endocrinol 10:13–14
- 11. Creatsas G, Deligeoroglou E, Cardamakis E, Aravantinos D (1994) XY pure gonadal (testicular) dysgenesis: brief report of a familiar case. Adolesc Pediatr Gynecol 7:34–37
- 12. Creatsas G, Salakos N, Averkiou M, Miras K, Aravantinos D (1992) Endocrinological profile of oligomenorrheic strenuously exercising adolescents. Int J Gynecol 38:215–221
- Deligeoroglou E, Athanasopoulos N, Tsimaris P, Dimopoulos KD, Vrachnis N, Creatsas G
   (2010) Evaluation and management of adolescent amenorrhea. Ann NY Acad Sci 1205:23–32
- Deligeoroglou E, Karountzos V, Creatsas G (2013) Abnormal uterine bleeding and dysfunctional uterine bleeding in pediatric and adolescent gynecology. Gynecol Endocrinol 29 (1):74–78